These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38601323)

  • 1. Modeling of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-2 considering the protein flexibility by using molecular dynamics and cross-docking.
    Valdés-Albuernes JL; Díaz-Pico E; Alfaro S; Caballero J
    Front Mol Biosci; 2024; 11():1374364. PubMed ID: 38601323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational study of the binding orientation and affinity of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-1 considering the protein flexibility by using molecular dynamics and cross-docking.
    Castillo-Campos L; Velázquez-Libera JL; Caballero J
    Front Mol Biosci; 2023; 10():1215499. PubMed ID: 37426421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches.
    Bhowmick S; Saha A; AlFaris NA; ALTamimi JZ; ALOthman ZA; Aldayel TS; Wabaidur SM; Islam MA
    J Mol Graph Model; 2022 Mar; 111():108113. PubMed ID: 34959151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.
    Stasiulewicz A; Maksymiuk AW; Nguyen ML; Bełza B; Sulkowska JI
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbial based natural compounds as potential inhibitors for SARS-CoV-2 Papain-like protease (PLpro): a molecular docking and dynamic simulation study.
    Rahul S; Sarkar A
    J Biomol Struct Dyn; 2022; 40(24):13848-13858. PubMed ID: 34730069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A computational essential dynamics approach to investigate structural influences of ligand binding on Papain like protease from SARS-CoV-2.
    Singh E; Jha RK; Khan RJ; Kumar A; Jain M; Muthukumaran J; Singh AK
    Comput Biol Chem; 2022 Aug; 99():107721. PubMed ID: 35835027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation.
    Tian X; Zhao Q; Chen X; Peng Z; Tan X; Wang Q; Chen L; Yang Y
    Front Pharmacol; 2022; 13():817715. PubMed ID: 35264955
    [No Abstract]   [Full Text] [Related]  

  • 8. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.
    Sivakumar D; Stein M
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34071582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some
    Amin SA; Ghosh K; Gayen S; Jha T
    J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising antivirals for PLpro of SARS-CoV-2 using virtual screening, molecular docking, dynamics, and MMPBSA.
    Kumari R; Kumar V; Dhankhar P; Dalal V
    J Biomol Struct Dyn; 2023 Jul; 41(10):4650-4666. PubMed ID: 35510600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacophore model-aided virtual screening combined with comparative molecular docking and molecular dynamics for identification of marine natural products as SARS-CoV-2 papain-like protease inhibitors.
    Thangavel N; Albratty M
    Arab J Chem; 2022 Dec; 15(12):104334. PubMed ID: 36246784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations.
    Tumskiy RS; Tumskaia AV; Klochkova IN; Richardson RJ
    Comput Biol Med; 2023 Feb; 153():106449. PubMed ID: 36586228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent Inhibitors.
    Garland O; Ton AT; Moradi S; Smith JR; Kovacic S; Ng K; Pandey M; Ban F; Lee J; Vuckovic M; Worrall LJ; Young RN; Pantophlet R; Strynadka NCJ; Cherkasov A
    J Chem Inf Model; 2023 Apr; 63(7):2158-2169. PubMed ID: 36930801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.
    Valipour M
    Eur J Med Chem; 2022 Oct; 240():114572. PubMed ID: 35797899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery.
    Amin SA; Ghosh K; Singh S; Qureshi IA; Jha T; Gayen S
    Mol Divers; 2022 Feb; 26(1):215-228. PubMed ID: 33675510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19.
    Balkrishna A; Mittal R; Arya V
    Curr Pharm Biotechnol; 2021; 22(10):1350-1359. PubMed ID: 33176643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying structural-functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation.
    Rao P; Patel R; Shukla A; Parmar P; Rawal RM; Saraf M; Goswami D
    Mol Divers; 2022 Feb; 26(1):309-329. PubMed ID: 33825097
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Huynh T; Cornell W; Luan B
    Front Chem; 2020; 8():624163. PubMed ID: 33614597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benchmarked molecular docking integrated molecular dynamics stability analysis for prediction of SARS-CoV-2 papain-like protease inhibition by olive secoiridoids.
    Thangavel N; Albratty M
    J King Saud Univ Sci; 2023 Jan; 35(1):102402. PubMed ID: 36338939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity.
    Barretto N; Jukneliene D; Ratia K; Chen Z; Mesecar AD; Baker SC
    J Virol; 2005 Dec; 79(24):15189-98. PubMed ID: 16306590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.